The widely used and only treatment in malaria prevention in pregnant women may no longer be effective in treating the disease. As such, pregnant women are at a higher risk of malaria infection in areas where drug resistance to sulfadoxine-pyrimethamine is rising. This is according to a study led by a team at the Liverpool School of Tropical Medicine (LSTM) and published in the Lancet Infectious Diseases.